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Preventive Gabapentin versus Pregabalin to 
Decrease Postoperative Pain after Lumbar 
Microdiscectomy: A Randomized Controlled Trial  
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Syed Ather Enam1, Salman Sharif 3, Ghulam Murtaza4  
1The Aga Khan University Hospital, Karachi, Pakistan
2Baqai Medical College, Karachi, Pakistan
3Liaquat National Hospital, Karachi, Pakistan
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Study Design: Randomized controlled trial.
Purpose: The purpose of this study was to compare pregabalin and gabapentin for mean postoperative visual analog score (VAS) for 
pain in patients undergoing single-level lumbar microdiscectomy for intervertebral disc prolapse at a tertiary care hospital.
Overview of Literature: Pregabalin has a superior pharmacokinetic profile and analgesic effect at lower doses than gabapentin; 
however, analgesic efficacy must be established during the perioperative period after lumbar spine surgery.
Methods: This randomized controlled trial was carried out at our institute from February to October 2011 on 78 patients, with 39 
participants in each study group. Patients undergoing lumbar microdiscectomy were randomized to group A (gabapentin) or group B 
(pregabalin) and started on trial medicines one week before surgery. The VAS for pain was recorded at 24 hours and one week post-
operatively. 
Results: Both groups had similar baseline variables, with mean ages of 42 and 39 years in groups A and B, respectively, and a major-
ity of male patients in each group. The mean VAS values for pain at 24 hours for gabapentin vs. pregabalin were comparable (1.97±0.84 
vs. 1.6±0.87, respectively; p=0.087) as were the results at one week after surgery (0.27±0.45 vs. 0.3±0.46, respectively; p=0.79). None 
of the patients required additional analgesia postoperatively. After adjusting for age and sex, the VAS value for group B patients was 
0.028 points lower than for group A patients, but this difference was not statistically significant (p=0.817, R2=0.018).
Conclusions: Pregabalin is equivalent to gabapentin for the relief of postoperative pain at a lower dose in patients undergoing lum-
bar microdiscectomy. Therefore, other factors, such as dose, frequency, cost, pharmacokinetics, and side effects of these medicines, 
should be taken into account whenever it is prescribed. 
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Introduction
Effective pain control after major surgical procedures not 
only affects patient satisfaction but also the morbidity and 
length of hospital stay [1-3]. Prevention and treatment 
of postoperative pain continue to be major challenges in 
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postoperative care for humanitarian, ethical, and medi-
cal reasons [4]. One of the most important predictors of 
chronic postoperative pain is the severity of acute postop-
erative pain [5]. 
Despite major advancements in the understanding of 
pain and its control, almost 80% patients still experience 
significant postoperative pain [6]. The risk of inappropri-
ate pain control is especially high in patients undergoing 
surgery for chronic low back pain, who often develop 
tolerance to strong analgesics [7]. The use of multimodal 
treatments has reduced the side effects and doses required 
for adequate analgesia [8-10]. Multiple mechanisms sug-
gest that a combination of different analgesics will reduce 
side effects and opioid dependence and will synergistically 
enhance analgesia [8].
Pregabalin is a structural analog of gamma-aminobu-
tyric acid (GABA) and shares some characteristics with 
its precursor gabapentin. Its mechanism of ac tion is the 
same as gabapentin, but it has a superior pharmacokinetic 
profile [11]. Its efficacy for the treatment of acute pain 
is similar to that of gabapentin; however, it has greater 
bioavailability, linear pharmacokinetics, requires lower 
dose titration, and has a shorter time required to achieve 
an optimal analgesic effect [12,13]. Although structurally 
similar to gabapentin, pregabalin has greater analgesic ef-
ficacy in rodent models of neuropathic pain [14,15] with 
lower intersubject variability. Pregabalin also appears to 
be more effective for the control of acute nociceptive pain 
after surgery and the reduction of both opioid depen-
dence and anxiety [16,17]. In previous studies, the visual 
analog score (VAS) values for pain 24 hours after surgery 
for gabapentin versus pregabalin were 3.6±1.4 [18] versus 
1.73±2.02 [19] (mean±standard deviation).
A few studies have addressed the use of pregabalin as 
part of an analgesic regimen for lumbar spine surgery spe-
cifically. However, pregabalin was either compared to pla-
cebo or there were limitations in the study design, accord-
ing to the pharmacological properties of the drugs, i.e., 
the drug was used just before the surgery, but it requires 
at least a week to yield effective analgesia [20]. Thus, inter-
ventional drugs should be administered one week prior to 
surgery for maximal benefit at the time of surgery. 
Because the preventive use of GABA analogs before sur-
gery reduces both side effects and the need for postopera-
tive analgesia, both gabapentin and pregabalin should be 
compared in the same study to determine the drug with 
the more favorable outcome (better safety and pharma-
cokinetic profiles) based on valid evidence. Therefore, we 
intended to compare lower doses of pregabalin to gaba-
pentin in terms of the mean VAS value for postoperative 
pain in patients undergoing single-level lumbar microdis-
cectomy for intervertebral disc prolapse at a tertiary care 
hospital. We hypothesized that the pain in the pregabalin 
group would be less than that in the gabapentin group.
Materials and Methods
This parallel-group, single-blinded, randomized con-
trolled trial was conducted by the department of neuro-
surgery, Aga Khan University Hospital, from February to 
October 2011, and included 78 patients who underwent 
lumbar microdiscectomy. The Ethical Review Commit-
tee (173-SUR-ERC-10) approved this study (Registered 
at Clinical Trials.gov [NCT02120703]). Patients between 
30 and 60 years of age who underwent elective lumbar 
microdiscectomy for intervertebral disc prolapse were 
randomized to either group A (gabapentin, trade name: 
neogab, Hilton Pharma, Pakistan) or group B (pregabalin, 
trade name: zeegap, Hilton Pharma, Karachi, Pakistan) 
using a computer-generated table for the desired sample 
size. To reduce confounding effects, we excluded patients 
with the following: (1) microdiscectomy at two or more 
vertebral levels, (2) use of instrumentation (e.g., pedicle 
screw fixation, hooks, etc.), (3) history of steroids or al-
cohol use, (4) multiple comorbidities (e.g., renal failure, 
chronic liver disease, etc.), (5) use of anticonvulsant drugs, 
(6) spinal deformity, (7) obesity (body mass index >30), (8) 
inability to understand and respond to the VAS, and (9) 
known allergy to GABA analogs.
We calculated sample size using World Health Organi-
zation software that employed the formula for hypothesis 
testing of two population means (one-sided). In previous 
studies, the VAS values for pain 24 hours after surgery for 
gabapentin versus pregabalin were 3.6±1.4 [18] versus 
1.7±2.02 [19] (mean±standard deviation). At a 5% level 
of significance and a 99% power, a sample size of 36 was 
required for each intervention arm. With an expected 
dropout rate of 10% (three subjects per group), 39 patients 
were enrolled per group.
Informed consent was obtained in the preoperative 
clinic upon registration of the patient for surgery. A com-
puter-generated randomization sequence was generated 
by a statistician. Patients were administered pregabalin 
or gabapentin one week before surgery at doses of 75 mg 
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and 200 mg twice daily, respectively. Two weeks’ worth of 
medication was supplied by the research team in a sealed 
opaque envelope with the randomization number writ-
ten on it. Trial medicines were continued postoperatively, 
along with tramadol (50 mg, three times a day), 500 mg 
paracetamol+pseudoephedrine (one tablet, three times a 
day) and ibuprofen (400 mg, three times a day). Patients 
were also offered morphine as patient-controlled intermit-
tent analgesia (PCIA); any additional analgesia used in 24 
hours in the form of PCIA was recorded (effect modifier). 
Lumbar microdiscectomy was performed by a single 
surgeon. Postoperatively, all patients were mobilized after 
24 hours with the help of a physiotherapist and ambulated 
at least 15–20 meters. Immediately thereafter, patients 
were approached by a registered nurse to register the VAS 
value for pain. The nurse was unaware of the trial medi-
cine and hypothesis. Patients were discharged on the sec-
ond postoperative day, prescribed the same medications 
mentioned above, and followed up in the clinic after one 
week. Patient was mobilized in the clinic and VAS was 
recorded by a registered nurse. Patients were discharged 
from the trial thereafter, and medications were continued 
at the discretion of the primary surgeon.
SPSS ver. 16 (SPSS Inc., Chicago, IL, USA) was used for 
data analysis. Continuous variables (i.e., age, pain score, 
and postoperative analgesia consumption) were reported 
as the mean±standard deviation. Categorical variables (i.e., 
sex) were reported as proportions. Outcomes (i.e., VAS 
values after 1 day and 1 week) were compared between 
the groups by the student’s t-test. Confounding and effect 
modifying variables (i.e., age, sex, and amount of addi-
tional analgesia needed) were analyzed by multiple linear 
regression. p-values less than 0.05 were considered statis-
tically significant.
Results
A total of 122 patients were evaluated, and 78 patients 
were enrolled in the study. There were 39 participants in 
each group (Fig. 1). Both groups were comparable for 
baseline demographic variables (Table 1).
The mean VAS values for pain for both groups were 
comparable, both 24 hours and one week after surgery 
(24 hours: 1.97±0.84 vs. 1.6±0.87, p=0.087 and 1 week: 
0.27±0.45 vs. 0.3±0.46, p=0.79, respectively) (Table 2). 
No patient required additional analgesia postoperatively. 
Patients in group A reported increased thirst compared 
to those in group B; otherwise, no adverse effects were re-
ported by the research participants.
The multivariable linear regression model of the VAS 
Table 1. Baseline comparison of variables
Variable Gabapentin  (n=39)
Pregabalin
(n=39)
Age    42±8.9   39±12
Sex
    Female 12 (30) 10 (25)
    Male 27 (70) 29 (75)
Body mass index 26.8±2.9 27.1±1.9
Comorbids
   Diabetes mellitus      4 (10.2)      5 (12.8)
   Hypertension      5 (12.8)    3 (7.6)
   COPD    1 (2.5)    1 (2.5)
   Others    3 (7.6)      4 (10.2)
Duration of symptoms (wk)   6.7±2.9   7.3±3.5
Values are presented as number (%).
COPD, chronic obstructive pulmonary disease.
Fig. 1. Flow diagram of participants.
Assessed for 
eligibility 
(n=122)
Not meeting inclusion 
criteria (21)
Excluded (n=23)
  7 (more than two levels)
  5 (multiple comorbids)
  4 (obesity)
  1 (steroids)
  1 (pregnancy and lactation)
  1 (allergic to drugs)
  4 (declined to participate) 
Allocated to 
Gabapentin 
(n=39)
Allocated to 
Pregabalin 
(n=39)
Enrollment
Randomized 
(n=78)
Allocation
Lost to follow-up 
(n=0)
Analyzed 
(n=39 )
Lost to follow-up 
(n=0)
Analyzed 
(n=39 )
Follow-up
Analysis
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for pain at 1 week consisted of the main exposure (in-
tervention) and covariates (age and sex). After adjusting 
for age and sex, the VAS value for group B patients was 
0.028 points lower than that for the group A patients, but 
this difference was not statistically significant (p=0.817, 
R2=0.018). 
Discussion
This randomized controlled trial compared pregabalin 
and gabapentin for mean postoperative pain in patients 
undergoing single-level lumbar microdiscectomy for in-
tervertebral disc prolapse. We found that both drugs were 
equivalent; thus, we failed to prove our hypothesis that the 
pain in the pregabalin group would be less than that in the 
gabapentin group.
The concept of multimodal pain management, that is, 
the reduction of adverse effects due to lower doses of pain 
medications, has evolved over time [21]. After spinal sur-
gery, opioids and nonsteroidal anti-inflammatory drugs 
have been the standards of treatment. The use of these 
drugs at high doses, however, has been associated with 
side effects, like drowsiness, constipation, urinary reten-
tion, etc. [10,21], which has led to the popularity and fre-
quent use of newer, anticonvulsant therapies [22].
Pregabalin and its precursor, gabapentin, are analogs 
of the inhibitory neurotransmitter, GABA. These com-
pounds have anticonvulsant, antihyperalgesic, and anxio-
lytic effects, and both bind to the alpha 2-delta (α2-δ) sub-
unit of presynaptic, voltage-gated calcium channels. The 
probable mechanism of action of pregabalin/gabapentin is 
to reduce the release of excitatory neurotransmitters (e.g., 
glutamate, substance P, calcitonin, noradrenaline, gene-
related peptide) by inhibiting calcium influx via calcium 
channels [23].
The pharmacological properties of pregabalin, however, 
are not identical to those of gabapentin. Although structur-
ally similar to gabapentin, pregabalin has greater analgesic 
efficacy. Pregabalin is pharmacologically superior to 
gabapentin due to its higher bioavailability (90% vs. 33%–
66%), more rapid absorption (peak plasma level: 1 hour 
vs. 3–4 hours), and linear increase in plasma concentra-
tions when its dose is increased [11]. The lower doses of 
pregabalin required for its analgesic effect, compared to 
gabapentin, result in better tolerance and fewer side 
effects, making its use more advantageous. Although not 
a part of this study, the observation was made that, even 
at these low doses, patients on gabapentin complained of 
thirst. No major side effects were reported by patients in 
the pregabalin group at these doses; however, the sample 
size in our study is too small to make conclusions about 
the side effect profile. 
Multiple studies have shown the beneficial effects of 
pregabalin and gabapentin administered just before sur-
gery, compared to their postoperative administration [19]. 
The CSF levels of pregabalin required to elicit the desired 
amount of pain reduction may require from 6 hours to 
one week after oral administration [24] and the beneficial 
pain controlling effects may take up to 1 week. We thus 
designed our study to administer pregabalin to patients 
at least one week before surgery, so as to obtain its maxi-
mum analgesic effects. We also used a lower dose of pre-
gabalin to decrease any possible side effects. The analgesic 
activity and opioid-sparing effects of pregabalin are negli-
gibly affected by doses of either 300 or 600 mg, as shown 
previously by Apfelbaum et al. [6].
The immediate postoperative period is the most pain-
ful for patients undergoing microdiscectomy, a procedure 
that usually lasts 1–2 hours [25-28]; optimal CSF con-
centrations of drug may not be available during this most 
immediate and painful period for the patient [24]. In our 
study, we prescribed lower doses of both pregabalin and 
gabapentin than those used in previous studies, but the 
VAS values for pain 24 hours after surgery were compara-
ble to those reported in the literature [29]. Similarly, both 
drugs provided comparable pain relief. 
Table 2. Outcome variables
Outcome Gabapentin Pregabalin    p-value
VAS at 24 hours 1.97±0.84 1.6±0.87     0.087a)
VAS at 1 week 0.27±0.45 0.3±0.46 0.79
Values are presented as number (%).
VAS, visual analog score.
a)Student’s t-test.
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We used the VAS to record postoperative pain control, 
as it has been shown to be a reliable, reproducible, and 
comparable objective scoring system by a number of in-
vestigators. It is considered the standard measurement 
tool for recording the extent of pain control. No patients 
required additional analgesia postoperatively, and no 
PCIA was used by any patient. This fact might contrib-
ute to the quality of the study, as the masking effects of 
morphine on analgesia and side effects were removed. 
The weakness of our study is that it lacked a placebo arm, 
which may have clarified any interactions between the 
drugs used in this study. 
Conclusions
Preventive use of low-dose pregabalin is equivalent to 
that of gabapentin for the relief of postoperative pain in 
patients undergoing spine surgery. Therefore, we recom-
mend the preferential use of pregabalin over gabapentin 
based on its superior pharmacokinetics and pharmacody-
namics.
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